Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

Serum Levels of Fibroblast Growth Factor 23 and Sclerostin in Relation to Serum Calcium Level in COVID 19 Patients

Hypocalcemia is associated with COVID-19 patients and is linked to poor prognosis, Fibroblast growth factor 23 (FGF23) and Sclerostin inhibit vitamin D activation and are linked to hypocalcemia.

Levels of FGF23 and Sclerostin in COVID-19 patients will be detected and correlated to calcium levels.

COVID 19 is a current worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 "SARS-CoV-2". Hypovitaminosis D and hypocalcaemia have been reported to be associated with COVID 19 infection, they are considered good biomarkers of clinical severity of COVID 19. Poor prognosis related to hypocalcemia is increased in elderly patients.

Fibroblast growth factor 23 and sclerostin are secreted from the bone, they decrease active vitamin D levels. Their levels and their relation to calcium levels in COVID-19 patients will be detected.

Inclusion Criteria:

• Positive COVID 19 (Mild to moderate - severe to critical).

Exclusion Criteria:

• known diagnosis of CKD.
• Known parathyroid disease.
• Use of phosphate binder therapy within the past 3 months.
• Use of calcium therapy within the past 3 months
• Treatment with 25(OH) vitamin D or 1,25 (OH)(2) D
• Underlying metabolic bone disease.
• Underlying renal phosphate wasting disorder.